April 01, 2024

Cannabis Company Leafly (LFLY) Announces Earnings, Share Price Higher on Report

On Friday, the online cannabis discovery marketplace, Leafly Holdings, Inc. (LFLY) announced its Q4 and FY 2023 financial results. Q4 EPS improved greatly from a year ago which was reported at ($0.22) vs a year ago ($3.34). Additionally, Q4 revenues were $9.7M vs Factset $9.5M. The company’s commitment to its operational discipline in 2023 resulted… [Read More]
3M sign outside building
April 01, 2024

Treasuries Decline as US Factory Data Sparks Rate Speculation: Market Overview

US manufacturing shows growth for the first time since 2022, signaling a robust economy. Market participants are closely monitoring Federal Reserve speakers for insights into future monetary policy decisions. Solid US manufacturing data has led to a downturn in the bond market and a halt in stock market gains, as expectations grow that the Federal… [Read More]
March 28, 2024

Innovent Doses First Patient in Phase 3 Colon Cancer Trial

Innovent Biologics (HKEX: 01801) has dosed the first participant with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial for resectable MSI-H/dMMR[1] colon cancer (stage cT4 or cN+) neoadjuvant therapy. Innovent’s study is the first Phase 3 clinical trial in China to investigate MSI-H/dMMR colon cancer neoadjuvant immunotherapy. Dr. Zhou… [Read More]
March 28, 2024

PRISM Market Moves on Thursday: Restoration Hardware Shines, Estee Lauder Gains; Reddit and Braze Slip

US equities are trading mostly higher on Thursday at midday, after stocks rallied during Wednesday’s session.  Outperformers include energy, homebuilders, casinos, airlines, credit cards, food, and trucking, while machinery, biotech, managed care, cruise lines, and beverages are weaker. Treasuries are weaker, the Dollar index is up +0.1%, Gold is up +1.1%, Bitcoin futures are up… [Read More]
March 28, 2024

Nutriband Soars on Regulatory Path Overview for Transdermal Fentanyl Patch

Shares in Nutriband (Nasdaq: NTRB) climbed nearly 50% in morning trading on Thursday after the company outlined its planned clinical and regulatory path for its lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch. Nutriband stated that it will utilize the 505(b)(2) New Drug Application (NDA) regulatory pathway which limits the development required for products… [Read More]
March 28, 2024

Mainz Biomed Presents ColoAlert® Cancer Screening Innovation at 2024 UDH Congress

Molecular genetics diagnostics company, Mainz Biomed N.V. (Nasdaq: MYNZ) presented its ColoAlert® cancer screening innovation at the 39th UDH Congress in Fellbach, Germany this month. ColoAlert, the company’s flagship product, offers a highly accurate, easy-to-use, at-home colorectal cancer (CRC) screening kit with  advanced tumor DNA analysis technology, which significantly improves early detection rates, a crucial… [Read More]
March 28, 2024

PRISM Emerging Psychedelics Spotlight: Cybin, Inc.

Psychedelic-based therapeutics company, Cybin, Inc. (NYSE American: CYBN) has achieved an impressive number of key milestones this month, and the investment community is taking note. The company’s share price has risen by 5.75% over the past month, reflecting investor interest in the emerging psychedelics segment, and confidence in the company’s strategy and trajectory to date…. [Read More]
March 28, 2024

Intelligent Scopes Brings AI to Colon Cancer Detection

Privately-held company, Intelligent Scopes Corporation, specializes in developing state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology. This month, the company announced the completion of its Helga AI-GEP™ AI platform for gastroenterology. Helga AI-GEP™ will offer computer-aided devices for detection, classification and characterization of lesions and tissue irregularities in the colon (colon… [Read More]
Tesla Motors
March 28, 2024

Tesla Faces $350 Billion Market Value Erosion Amid Poor Stock Performance

First-quarter struggles mark one of its worst periods Declining delivery forecasts dent investor confidence Tesla Inc.’s ($TSLA)  stock has recently shown some resilience after a significant downturn earlier this year, yet investors remain hesitant due to uncertainties about the company’s recovery prospects. With first-quarter delivery figures expected next week, the decreasing projections have set the… [Read More]